Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afluxin® vs Placebo in Mild to Moderate GERD
NCT06984484Recruiting
- Sponsor
- Devintec Pharma
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Devintec Pharma. Primary endpoint: Proportion of responders at 7 days. Started Jul 2025; status: recruiting.
02
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06984484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984484.